Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab

Patient-reported outcomes were evaluated in EPCORE NHL-1 in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) treated with epcoritamab monotherapy (NCT03625037).

Source: Clinical Lymphoma, Myeloma and Leukemia - November 26, 2023 Category: Hematology Authors: Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Nurgul Kilavuz, Catherine Thieblemont Tags: Original Study Source Type: research